What are the main products of the company?

Main products include injections, medicines, western medicines, infusions, IV solutions, parenteral solutions, tablets, capsules, small volume injections, and inhalations.

What is the mechanism of action for Azithromycin?

It acts by binding to the P site of the 50S ribosomal subunit, inhibiting RNA-dependent protein synthesis and stimulating the dissociation of peptidyl t-RNA from ribosomes.

Azithromycin Tablets 250mg GMP Manufacturer

Name: Azithromycin Tablets 250mg GMP Manufacturer
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 758230252

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.01-0.10

100,000 Pieces

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

250mg

Suitable for

Elderly, Adult

State

Solid

Shape

Tablet

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Production Line

GMP Approved

Transport Package

Carton

Specification

250mg

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

GMP Approved Production: Manufactured in GMP approved production lines ensuring high quality standards.

Leading Manufacturer: Produced by Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a top 100 Chinese pharma enterprise.

70 Years Experience: Company has a business history of seventy years in R&D, manufacture and sales.

Advanced Technology: Full automation control and information control in production and logistics processes.

Global Export Reach: Products exported to more than 80 countries across Asia, Americas, Europe, Oceania, and Africa.

Strong R&D Team: Powerful R&D team with achievements in scientific research and technological innovation projects.

Wide Product Range: Specializes in intravenous infusion, tablets, capsules, and recently API production.

Antibiotic Efficacy: Macrolide antibiotic that inhibits protein synthesis with rapid absorption and distribution.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.